Nature Communications (Sep 2022)
Inhibition of UBA6 by inosine augments tumour immunogenicity and responses
- Lei Zhang,
- Li Jiang,
- Liang Yu,
- Qin Li,
- Xiangjun Tian,
- Jingquan He,
- Ling Zeng,
- Yuqin Yang,
- Chaoran Wang,
- Yuhan Wei,
- Xiaoyue Jiang,
- Jing Li,
- Xiaolu Ge,
- Qisheng Gu,
- Jikun Li,
- Di Wu,
- Anthony J. Sadler,
- Di Yu,
- Dakang Xu,
- Yue Gao,
- Xiangliang Yuan,
- Baokun He
Affiliations
- Lei Zhang
- Department of Gastroenterology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine
- Li Jiang
- Department of Gynecology and Obstetrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Liang Yu
- Department of Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Qin Li
- Department of Oncology, Beijing Friendship Hospital, Capital Medical University
- Xiangjun Tian
- Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center
- Jingquan He
- Biotree Institute of Health
- Ling Zeng
- Department of Gastroenterology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine
- Yuqin Yang
- Department of Laboratory Animal Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Chaoran Wang
- Department of Oncology, Beijing Friendship Hospital, Capital Medical University
- Yuhan Wei
- Department of Oncology, Beijing Friendship Hospital, Capital Medical University
- Xiaoyue Jiang
- Department of Oncology, Beijing Friendship Hospital, Capital Medical University
- Jing Li
- Department of Clinical Laboratory Science, The Affiliated Hospital of Qingdao University
- Xiaolu Ge
- Department of Gastroenterology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine
- Qisheng Gu
- Department of Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Jikun Li
- Department of Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Di Wu
- Department of Biostatistics, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- Anthony J. Sadler
- Hudson Institute of Medical Research
- Di Yu
- Diamantina Institute, Faculty of Medicine, The University of Queensland
- Dakang Xu
- Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Yue Gao
- Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine
- Xiangliang Yuan
- Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Baokun He
- Department of Gastroenterology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-33116-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
The metabolic environment of tumours has wide-ranging effects on the anti-tumour immune response and the outcome of immune therapy. Authors show here that the purine metabolite inosine enhances tumour immunogenicity and thus immune checkpoint blockade therapy response by inhibiting the ubiquitin-activating enzyme UBA6 in tumour cells.
